Navigation Links
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
Date:6/5/2008

bout MPS IVA

Mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A Syndrome) is a disease characterized by deficient activity of N-acetylgalactosamine-6- sulfatase (GALNS) causing excessive lysosomal storage of keratan sulfate (KS). This excessive storage causes a systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance. Malformation of the thorax impairs respiratory function, and odontoid hypoplasia and ligamentous laxity cause cervical spinal instability and potentially cord compression. Other symptoms may include hearing loss, corneal clouding, and heart valvular disease. Initial symptoms often become evident in the first five years of life. Depending on severity of the disease, age of diagnosis will vary.

The rate of incidence of MPS IVA is as yet unconfirmed, but estimates vary between 1 in 200,000 live births to 1 in 300,000 live births. Approximately 370 patients worldwide are currently registered in The International Morquio Organization (IMO) survey. An estimated 1,100 patients in the developed world have MPS VI and an estimated 3,000 patients in the developed world have MPS I.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular in
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin to Host Research and Development Day June 5th
2. BioMarin to Present at the Bank of America Healthcare Conference
3. BioMarin Announces First Quarter 2008 Financial Results
4. BioMarin to Present at the Morgan Stanley Healthcare Conference
5. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
6. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
9. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
10. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
11. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... research platform uses a laser to measure ... stress and heating, an approach likely to ... and batteries., This new technique, called nanomechanical ... and the surface stress of microscale structures ... the merits of surface-stress influence on mechanical ...
(Date:8/28/2014)...  Next month, executives from clinical trial marketing firm BBK ... with Patient-Centered Clinical Trials 2014 , to be held ... , September 4-5. Patient recruitment experts Bonnie A. Brescia ... will share insights on the benefits of employing an effective ... from media to mobile apps – can be used to ...
(Date:8/28/2014)... TALLAHASSEE, Fla. Exciting new work by a Florida ... molecular system that can take your temperature, emit white ... , And, the molecule looks like a butterfly. , ... and Biomedical Engineering in the FAMU-FSU College of Engineering, ... ago, but has continued to discover that his creation ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 ... wholesale construction materials, selected SoundConnect to ... their cloud based audio and web conferencing platform ... to support PrimeSource’s employees’ needs. SoundConnect delivers ... , PrimeSource Building Products will be utilizing ...
Breaking Biology Technology:New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2
... Sequenom, Inc. (NASDAQ: SQNM ), a life ... it and its subsidiary Sequenom Center for Molecular Medicine® ... from Silicon Valley Bank’s San Diego-based team. Sequenom will ... and commercialization of new products and other near term ...
... coated with a drug-loaded polymer in an attempt to ... neurological symptoms, such as those associated with an epileptic ... study published today, 2 June 2011, in IOP Publishing,s ... a novel technology to precisely modulate individual neurons in ...
... Female mosquitoes are efficient carriers of deadly diseases such as ... million deaths and hundreds of millions of cases. ... these mosquitoes use exhaled carbon dioxide as a vital cue. ... of mosquitoes, which would help control the spread of diseases ...
Cached Biology Technology:Sequenom Enters Into New $30.0 Million Credit Facility 2Sequenom Enters Into New $30.0 Million Credit Facility 3Sequenom Enters Into New $30.0 Million Credit Facility 4New technology could inspire brain implant for detecting and treating seizures 2New findings by UCR scientists hold big promise for fight against mosquito-borne diseases 2New findings by UCR scientists hold big promise for fight against mosquito-borne diseases 3
(Date:8/28/2014)... A new study reports that an expansion of marine ... perform key ecological functions. According to investigators from ... at protecting fish have focused on saving the largest ... species that provide key and difficult-to-replace ecological functions. ... are performed by fish species that also are food ...
(Date:8/28/2014)... than traditional cigarettes, but still release toxins into ... USC. , Scientists studying secondhand smoke from e-cigarettes ... harmful particles, with close-to-zero exposure to organic carcinogens. ... in second-hand e-cigarette smoke were found to be ... levels of polycyclic aromatic hydrocarbons cancer-causing organic ...
(Date:8/28/2014)... Minn. A Mayo Clinic researcher and his collaborators ... up and enhance the process of re-engineering cells for ... uses network biology methods to aid stem cell engineering. ... engineering are described in two back-to-back papers in the ... a broad range of uses for all types of ...
Breaking Biology News(10 mins):Study finds marine protected areas inadequate for protecting fish and ocean ecology 2Second-hand e-cig smoke compared to regular cigarette smoke 2New tool aids stem cell engineering for medical research 2
... CITY, Calif. , Dec. 11, 2013  DigitalPersona, ... solutions, today announced that the DigitalPersona ® ... been certified by the National Institute of Standards ... testing program to meet the United States Government,s  ...
... Mothers get all the attention. But a study led by ... conception may play an equally important role in the health ... effects of current Western diets and of food insecurity. ... is found in a range of green leafy vegetables, cereals, ...
... Dec. 10, 2013  KaloBios Pharmaceuticals, Inc. (Nasdaq: ... an ongoing multi-center Phase 1 study of KB004, an ... developing as a treatment for hematologic malignancies. Forty-four ... for chemotherapy have been enrolled in the dose ...
Cached Biology News:DigitalPersona FingerJet Recognition Engine Top Performer in Recent MINEX Testing 2You are what your father eats 2KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 2KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 3KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 4KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 5